[Therapeutic and morphological observations derived from the use of cephalexin monohydrate].
D000293:Adolescent; D000328:Adult; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000188:drug therapy; D011512:Proteus Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy
D002511:Cephalosporins
Observaciones terapéuticas y farmacológicas derivadas del uso del monohidrato de cefalexina.